Zydus Lifesciences‘ share value continued its upward momentum for a second straight day, climbing 1% in early buying and selling on 15 April after receiving approval from the US Meals and Drug Administration (USFDA) for its Jaythari (Deflazacort) tablets.
In line with an change submitting, the corporate will manufacture Jaythari tablets, which can be found in 6 mg, 18 mg, 30 mg, and 36 mg strengths at its facility in Italy operated by Doppel Farmaceutici S.r.l.
Deflazacort is a corticosteroid used to deal with Duchenne muscular dystrophy (DMD) in sufferers aged 5 years and older.
With this newest approval, the Zydus Group now holds a complete of 424 approvals and has filed 492 Abbreviated New Drug Functions (ANDAs) because it started submitting in FY 2003-04.
Moreover, Zydus MedTech, an entirely owned subsidiary, established a brand new entity named Zydus MedTech (France) SAS on 10 April 2025.
The inventory recorded a 52-week excessive of Rs 1,323.90 on 9 August 2024 and a 52-week low of Rs 797.05 on 7 April 2025.
At 3:30 pm, the shares of Zydus Lifesciences closed 1.17% larger at Rs 879.05 on NSE.
Zydus Lifesciences Ltd Insights? Let the Analyst Information You.
Uninterested in guessing shares to commerce in day by day?
Unicorn Indicators empowers you with highly effective instruments like day by day inventory scans for Intraday, Swing & Investing, Market Predictions and rather more. Obtain the Unicorn Indicators app at this time and take management of your investments!
